Evidence map›Paper›PMID 27427920›Full record

Observational studyBone marrow transplantation2016

YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.

B Kornblit, T Wang, S J Lee, S R Spellman, X Zhu, K Fleischhauer, C Müller, M R Verneris, K Müller, J S Johansen and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

B KornblitThe Allogeneic Hematopoietic Cell Transplantation Laboratory, Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
T WangDivision of Biostatistics, Institute for Health & Society, Medical College of Wisconsin, Milwaukee, WI, USA.
S J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
S R SpellmanCenter for International Blood and Marrow Transplant Research, Minneapolis, MN, USA.
X ZhuCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
K FleischhauerInstitute for Experimental Cellular Therapy, Universitatsklinikum Essen KMT, Essen, Germany.
C MüllerZentrales Knochenmarkspender-Register Deutschland, Ulm, Germany.
M R VernerisDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
K MüllerDepartment of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
J S JohansenDepartment of Oncology and Medicine, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
L VindelovThe Allogeneic Hematopoietic Cell Transplantation Laboratory, Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
P GarredFaculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

YKL-40, also called chitinase-3-like-1 protein, is an inflammatory biomarker that has been associated with disease severity in inflammatory and malignant diseases, including AML, multiple myeloma and lymphomas. The objective of the current study was to assess the prognostic value of pretransplant recipient and donor plasma YKL-40 concentrations in patients with AML (n=624) or myelodysplastic syndrome (n=157) treated with allogeneic hematopoietic cell transplantation (HCT). In recipients, the plasma YKL-40 concentrations were increased when the HCT-comorbidity index was ⩾5 (P=0.028). There were no significant associations between plasma YKL-40 concentrations in recipients and any outcome measures. In donors with YKL-40 plasma concentrations above the age-adjusted 95th percentile, a trend toward increased grade II-IV acute GvHD in recipients was observed (adjusted hazard ratio 1.39 (95% confidence interval 1.00-1.94), P=0.050), with no significant associations with overall survival, treatment-related mortality or relapse. In conclusion, our study shows that YKL-40 does not aid risk stratification of patients undergoing allogeneic HCT, but suggests that YKL-40 may aid donor selection when multiple, otherwise equal, donors are available.

Indexed as

AdolescentAdultAgedAllograftsBlood DonorsChitinase-3-Like Protein 1Cohort StudiesDonor SelectionFemaleGraft vs Host DiseaseGrowth SubstancesHematopoietic Stem Cell TransplantationHumansLeukemia, Myeloid, AcuteMaleMiddle AgedCHI3L1 protein, humanChitinase-3-Like Protein 1Growth Substances

Identifiers

PMID27427920
PMCPMC5143177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.